# EDGAR Filing Document

**Accession Number:** 0001695076
**File Stem:** 0001012975-25-000705
**Filing Date:** 2025-11
**Character Count:** 12575
**Document Hash:** 8328f680130a205eba544498d9b78bce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001012975-25-000705.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001012975-25-000705

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251105

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pivotal bioVenture Partners Fund I, L.P.
- **CENTRAL INDEX KEY:** 0001695076

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42938
- **FILM NUMBER:** 251455673

**BUSINESS ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
- **BUSINESS PHONE:** (345) 949 1040

**MAIL ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Pivotal Venture Partners Fund I, L.P.
- **DATE OF NAME CHANGE:** 20170118
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pivotal bioVenture Partners Fund I U.G.P. Ltd
- **CENTRAL INDEX KEY:** 0001752847

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42938
- **FILM NUMBER:** 251455671

**BUSINESS ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
- **BUSINESS PHONE:** (415) 697-1002

**MAIL ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Pivotal bioVenture Partners Fund I U.G.P., Ltd
- **DATE OF NAME CHANGE:** 20180912
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pivotal bioVenture Partners Fund I G.P., L.P.
- **CENTRAL INDEX KEY:** 0001752862

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42938
- **FILM NUMBER:** 251455672

**BUSINESS ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
- **BUSINESS PHONE:** (415) 697-1002

**MAIL ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pivotal bioVenture Partners Fund I, L.P.<br><sub>(Last) (First) (Middle)</sub><br>501 SECOND STREET, SUITE 200<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94107<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Evommune, Inc. [ EVMN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-11-05 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pivotal bioVenture Partners Fund I G.P., L.P.<br><sub>(Last) (First) (Middle)</sub><br>501 SECOND STREET, SUITE 200<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94107<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Evommune, Inc. [ EVMN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-11-05 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pivotal bioVenture Partners Fund I U.G.P. Ltd<br><sub>(Last) (First) (Middle)</sub><br>501 SECOND STREET, SUITE 200<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94107<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Evommune, Inc. [ EVMN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-11-05 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series Seed Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 838886 | <sup>(1)</sup> | I | See footnotes<sup>(5)(10)</sup> |
| Series Seed Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 419441 | <sup>(1)</sup> | I | See footnotes<sup>(6)(8)(9)</sup> |
| Series A Preferred Stock | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 324578 | <sup>(2)</sup> | I | See footnotes<sup>(5)(10)</sup> |
| Series A Preferred Stock | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 908821 | <sup>(2)</sup> | I | See footnotes<sup>(6)(8)(9)</sup> |
| Series B Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 240756 | <sup>(3)</sup> | I | See footnotes<sup>(5)(10)</sup> |
| Series B Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 267367 | <sup>(3)</sup> | I | See footnotes<sup>(6)(8)(9)</sup> |
| Series C Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 36812 | <sup>(4)</sup> | I | See footnotes<sup>(5)(10)</sup> |
| Series C Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 36812 | <sup>(4)</sup> | I | See footnotes<sup>(6)(8)(9)</sup> |
| Series C Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 294502 | <sup>(4)</sup> | I | See footnotes<sup>(7)(8)(9)</sup> |

---

### Footnotes:

(1) The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering (the "IPO"), all shares of Series Seed Preferred Stock will be converted into shares of Common Stock.

(2) The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.

(3) The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.

(4) The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.

(5) Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL").

(6) Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I").

(7) Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II").

(8) The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.

(9) The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.

(10) The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.

**Signature:** /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner  
**Date:** 2025-11-05

**Signature:** /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I G.P., L.P., By: Robert Hopfner, Managing Partner  
**Date:** 2025-11-05

**Signature:** /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I U.G.P. Ltd., By: Robert Hopfner, Managing Partner  
**Date:** 2025-11-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**